However, MYC-driven B cell lymphomas, particularly HGBCL with MYC and BCL2 rearrangements, frequently silence surface BCR/CD79B expression, limiting the therapeutic reach of CD79B-directed ADCs and underscoring the need for complementary treatment strategies. This evidence concerns the gene CD79B and B-cell non-Hodgkin lymphoma.